Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Quantitative MRI and cerebrospinal fluid inflammatory mediators in Brazilian patients with relapsing-remitting multiple sclerosis before and after treatment with immunomodulators: a longitudinal study.

Ruocco HH, Brandão CO, Farias AS, Oliveira C, Oliveira EC, Cendes F, Damasceno BP, Santos LM.

Neuroimmunomodulation. 2012;19(5):277-82. doi: 10.1159/000335889. Epub 2012 Mar 30.

PMID:
22472803
2.

Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.

Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.

Mult Scler. 2008 May;14(4):479-84. doi: 10.1177/1352458507085555.

PMID:
18562504
3.

Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.

Gauthier SA, Glanz BI, Mandel M, Tsagkaropoulos A, Neema M, Stankiewicz J, Arora A, Duan Y, Liptak Z, Egorova S, Buckle GJ, Bakshi R, Guttmann CR, Khoury SJ, Weiner HL.

J Neurol Sci. 2009 Sep 15;284(1-2):116-9. doi: 10.1016/j.jns.2009.04.020. Epub 2009 May 9.

PMID:
19428028
4.

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, Gasperini C.

Mult Scler. 2012 Jan;18(1):64-71. doi: 10.1177/1352458511417481. Epub 2011 Aug 9.

PMID:
21828195
5.

Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.

Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P.

Mult Scler. 2012 Dec;18(12):1760-7. doi: 10.1177/1352458512447704. Epub 2012 May 8.

PMID:
22570359
6.

Intrathecal immunoglobulin G synthesis and brain injury by quantitative MRI in multiple sclerosis.

Brandão CO, Ruocco HH, Farias AS, Oliveira C, Cendes F, Damasceno BP, Santos LM.

Neuroimmunomodulation. 2006;13(2):89-95. Epub 2006 Oct 10.

PMID:
17033198
7.

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.

Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group.

Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.

PMID:
19542262
8.

Features of intrathecal immunoglobulins in patients with multiple sclerosis.

Di Pauli F, Gredler V, Kuenz B, Lutterotti A, Ehling R, Gneiss C, Schocke M, Deisenhammer F, Reindl M, Berger T.

J Neurol Sci. 2010 Jan 15;288(1-2):147-50. doi: 10.1016/j.jns.2009.09.016. Epub 2009 Oct 13.

PMID:
19828154
9.

Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.

Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Rinaldi L, Perini P, Gallo P, Filippi M.

Arch Neurol. 2009 Sep;66(9):1144-50. doi: 10.1001/archneurol.2009.174.

PMID:
19752305
10.

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.

Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.

Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909. Epub 2010 Feb 11.

PMID:
20150398
11.

Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual.

Durante L, Zaaraoui W, Rico A, Crespy L, Wybrecht D, Faivre A, Reuter F, Malikova I, Pommier G, Confort-Gouny S, Cozzone PJ, Ranjeva JP, Pelletier J, Boucraut J, Audoin B.

Mult Scler. 2012 May;18(5):587-91. doi: 10.1177/1352458511424589. Epub 2011 Sep 30.

PMID:
21965422
12.

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.

Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.

Mult Scler. 2002 Apr;8(2):119-23.

PMID:
11990868
13.

Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis.

Castellazzi M, Tamborino C, Cani A, Negri E, Baldi E, Seraceni S, Tola MR, Granieri E, Contini C, Fainardi E.

Mult Scler. 2010 Jul;16(7):883-7. doi: 10.1177/1352458510368051. Epub 2010 May 18.

PMID:
20483883
14.

A reassessment of the plateauing relationship between T2 lesion load and disability in MS.

Sormani MP, Rovaris M, Comi G, Filippi M.

Neurology. 2009 Nov 10;73(19):1538-42. doi: 10.1212/WNL.0b013e3181c06679. Epub 2009 Sep 30.

PMID:
19794123
15.

The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis.

Calabrese M, Federle L, Bernardi V, Rinaldi F, Favaretto A, Varagnolo MC, Perini P, Plebani M, Gallo P.

Mult Scler. 2012 Feb;18(2):174-80. doi: 10.1177/1352458511418550. Epub 2011 Aug 25.

PMID:
21868488
16.

Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.

Hedegaard CJ, Sellebjerg F, Krakauer M, Hesse D, Bendtzen K, Nielsen CH.

Mult Scler. 2011 May;17(5):567-77. doi: 10.1177/1352458510393771. Epub 2010 Dec 22.

PMID:
21177756
17.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.

PMID:
20488825
18.

Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study.

Calabrese M, Filippi M, Rovaris M, Bernardi V, Atzori M, Mattisi I, Favaretto A, Grossi P, Barachino L, Rinaldi L, Romualdi C, Perini P, Gallo P.

Mult Scler. 2009 Jan;15(1):36-41. doi: 10.1177/1352458508096686. Epub 2008 Aug 28.

PMID:
18755823
19.

Measures in the first year of therapy predict the response to interferon beta in MS.

Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalbán X.

Mult Scler. 2009 Jul;15(7):848-53. doi: 10.1177/1352458509104591.

PMID:
19542263
20.

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.

Pereira VC, Malfetano FR, Meira ID, Souza LF, Liem AM, Maiolino A, Alves-Leon SV.

Arq Neuropsiquiatr. 2012 Oct;70(10):774-9.

Supplemental Content

Support Center